China’s Henlius carves out $440M T-cell engager deal with Amberstone

The Senate Committee on Health, Education, Labor and Pensions (HELP) today questioned Heidi Overton, M.D., Ph.D., Trump’s pick for FDA commissioner, in a hearing marked by tightrope-walking on issues like vaccines, abortions, flavored…

Eli Lilly has committed $100 million in upfront and near-term payments to InnoCare Pharma to form a five-target drug discovery pact. The deal features up to $3.25 billion in milestones.

As two Big Pharma players in the autoimmune CAR-T space face unexpected safety setbacks, Kyverna Therapeutics is reporting long-term clinical data that showcase sustained efficacy alongside an unblemished safety profile for its potential…

Senator Todd Young (R-IN), chairman of the National Security Commission on Emerging Biotechnology, told Fierce why he's concerned about the growth of China's biopharma industry.

Merck & Co.’s Brunello trial has hit its primary endpoint, shedding light on the effects of a trispecific diabetic macular edema (DME) drug candidate that the Big Pharma bought in a $3 billion takeover.

Roche has penned a backloaded $2 billion deal with hematology biotech Atavistik Bio to develop allosteric small molecules for cardiometabolic diseases.

Acadia Pharmaceuticals’ phase 2 Alzheimer’s disease trial has missed its primary endpoint, but the company and analysts alike saw enough encouraging signals to support the continuation of a phase 3 program.

Fosun Pharma subsidiary Henlius Biotech has signed a $440 million biobucks deal with California-based Amberstone Biosciences to work on T-cell engagers.